VANCOUVER, British Columbia, July 7, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) advises that clinical results from its new tableted form of Immunoxel (Dzherelo) product demonstrated improved efficacy and shortened duration of treatment compared to the original liquid formulation. Ekomed is presenting these latest findings, as well as further results with Immunitor's V5 immunotherapy against TB, this week at the 3rd Asia Pacific Region Conference of the International Union Against Tuberculosis and Lung Disease held in Hong Kong on July 8-11, 2011.
Immunoxel has been demonstrated in a dozen published clinical trials to have a powerful effect against active tuberculosis, including the drug-resistant forms (MDR-TB and XDR-TB) and a significant improvement in TB/HIV patients vs standard therapy alone. The new tableted formulation has major advantages in terms of lower cost of production and of distribution, and is expected to exhibit much greater patient compliance due to simplified mode of administration. Although Immunoxel acts as an immunomodulator, it is currently sold as a herbal dietary supplement.
Immune Network recently signed a deal with Australian healthcare company Stirling Products Limited (ASX:STI) to make Immunoxel available and affordable for the patients who need such products. The market potential for products such as Immunoxel and V5 is large, since there are 9 million new cases of TB annually and 2 billion people are infected with the bacillus. Drug-resistant forms of TB – MDR-TB and XDR-TB and TB/HIV – are global health priorities.
The website for Immune Network is at http://www.immune-network.com.
The Immune Network Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8008.
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.